Zhang Wei, Garg Sanjay, Eldi Preethi, Zhou Fiona Huan-Huan, Johnson Ian R D, Brooks Doug A, Lam Frankie, Rychkov Grigori, Hayball John, Albrecht Hugo
Centre for Pharmaceutical Innovation and Development, Centre for Drug Discovery and Development, Sansom Institute for Health Research, and School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, SA 5001, Australia.
SAHMRI, North Terrace, Adelaide, SA 5001, Australia.
Int J Pharm. 2016 Nov 20;513(1-2):270-279. doi: 10.1016/j.ijpharm.2016.09.039. Epub 2016 Sep 12.
In recent years G protein-coupled receptors (GPCRs) have emerged as crucial tumorigenic factors that drive aberrant cancer growth, metastasis and angiogenesis. Consequently, a number of GPCRs are strongly expressed in cancer derived cell lines and tissue samples. Therefore a rational anti-cancer strategy is the design of nano-medicines that specifically target GPCRs to bind and internalise cytotoxic drugs into cancer cells. Herein, we report the genetic engineering of a self-assembling nanoparticle based on elastin-like polypeptide (ELP), which has been fused with gastrin releasing peptide (GRP). These nanoparticles increased intracellular calcium concentrations when added to GRP receptor positive PC-3 prostate cancer cells, demonstrating specific receptor activation. Moreover, GRP-displaying fluorescent labelled nanoparticles showed specific cell-surface interaction with PC-3 prostate cancer cells and increased endocytic uptake. These nanoparticles therefore provide a targeted molecular carrier system for evaluating the delivery of cytotoxic drugs into cancer cells.
近年来,G蛋白偶联受体(GPCRs)已成为驱动癌症异常生长、转移和血管生成的关键致瘤因子。因此,许多GPCRs在癌症衍生的细胞系和组织样本中强烈表达。因此,一种合理的抗癌策略是设计纳米药物,使其特异性靶向GPCRs,将细胞毒性药物结合并内化到癌细胞中。在此,我们报告了一种基于弹性蛋白样多肽(ELP)的自组装纳米颗粒的基因工程,该多肽已与胃泌素释放肽(GRP)融合。当添加到GRP受体阳性的PC-3前列腺癌细胞中时,这些纳米颗粒增加了细胞内钙浓度,证明了特异性受体激活。此外,展示GRP的荧光标记纳米颗粒显示出与PC-3前列腺癌细胞的特异性细胞表面相互作用,并增加了内吞摄取。因此,这些纳米颗粒为评估细胞毒性药物向癌细胞的递送提供了一种靶向分子载体系统。